0.79
-0.0548(-6.50%)
Currency In USD
| Previous Close | 0.84 |
| Open | 0.82 |
| Day High | 0.82 |
| Day Low | 0.77 |
| 52-Week High | 2.67 |
| 52-Week Low | 0.24 |
| Volume | 901,374 |
| Average Volume | 16.84M |
| Market Cap | 13.39M |
| PE | -0.34 |
| EPS | -2.34 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.28 |
| Change | -0.05 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of April 27, 2025 at a share price of $0.788. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $35.73 as of April 27, 2025 at a share price of $0.788.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) c
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
GlobeNewswire Inc.
Apr 15, 2025 11:30 AM GMT
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQHOUSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company d
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
GlobeNewswire Inc.
Mar 20, 2025 11:30 AM GMT
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”